CN105008394B - 治疗结肠直肠癌的方法 - Google Patents

治疗结肠直肠癌的方法 Download PDF

Info

Publication number
CN105008394B
CN105008394B CN201480016188.7A CN201480016188A CN105008394B CN 105008394 B CN105008394 B CN 105008394B CN 201480016188 A CN201480016188 A CN 201480016188A CN 105008394 B CN105008394 B CN 105008394B
Authority
CN
China
Prior art keywords
seq
smad7
smad
antisense oligonucleotide
colorectal cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480016188.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN105008394A (zh
Inventor
乔瓦尼·蒙泰莱奥内
塞尔瓦托·贝林薇雅
维蒂·弗朗西斯卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nogra Pharma Ltd
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of CN105008394A publication Critical patent/CN105008394A/zh
Application granted granted Critical
Publication of CN105008394B publication Critical patent/CN105008394B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201480016188.7A 2013-03-15 2014-03-14 治疗结肠直肠癌的方法 Active CN105008394B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361790488P 2013-03-15 2013-03-15
US61/790,488 2013-03-15
US201361847287P 2013-07-17 2013-07-17
US61/847,287 2013-07-17
PCT/EP2014/055195 WO2014140333A1 (en) 2013-03-15 2014-03-14 Methods of treating colorectal cancer

Publications (2)

Publication Number Publication Date
CN105008394A CN105008394A (zh) 2015-10-28
CN105008394B true CN105008394B (zh) 2021-10-22

Family

ID=50390057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480016188.7A Active CN105008394B (zh) 2013-03-15 2014-03-14 治疗结肠直肠癌的方法

Country Status (11)

Country Link
EP (1) EP2970419B8 (enExample)
JP (2) JP6502863B2 (enExample)
KR (1) KR102232623B1 (enExample)
CN (1) CN105008394B (enExample)
AU (1) AU2014229985B2 (enExample)
CA (1) CA2903597C (enExample)
ES (1) ES2673209T3 (enExample)
MX (1) MX363746B (enExample)
NZ (1) NZ711564A (enExample)
RU (1) RU2674147C2 (enExample)
WO (1) WO2014140333A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
KR101921014B1 (ko) 2008-11-13 2018-11-21 노그라 파마 리미티드 안티센스 조성물 및 그의 제조 및 사용 방법
EP2748611B1 (en) 2011-09-15 2016-11-23 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy
ES2732252T3 (es) 2012-04-18 2019-11-21 Nogra Pharma Ltd Procedimientos para tratar diabetes y/o promover la supervivencia de los islotes pancreáticos después del trasplante
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
US10473669B2 (en) 2014-05-09 2019-11-12 Nogra Pharma Limited Methods for treating inflammatory bowel disease
MX2017004973A (es) 2014-10-17 2017-12-07 Nogra Pharma Ltd Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7.
CA3000195A1 (en) * 2015-09-30 2017-04-06 Celgene Alpine Investment Company Ii, Llc Tlr modulators and methods of use
EP3420082A4 (en) 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005014011A1 (en) * 2003-08-11 2005-02-17 Giuliani S.P.A. Use of smad 7 antisense oligonucleotides (odn) for the treatment of diseases mediated by the nuclear transcription factor nf-kb
CN1788086A (zh) * 2003-04-02 2006-06-14 吉利亚尼国际有限公司 抗Smad7的反义寡核苷酸(ODN)及其在医药领域中的用途
CN101600460A (zh) * 2006-11-14 2009-12-09 香港大学 超声微泡介导的基因递送系统
CN102216458A (zh) * 2008-11-13 2011-10-12 朱利亚尼国际有限公司 反义组合物及其制备和使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
US7402574B2 (en) * 2004-03-12 2008-07-22 Avi Biopharma, Inc. Antisense composition and method for treating cancer
UA107562C2 (uk) * 2008-12-05 2015-01-26 Спосіб лікування псоріазу
EP2748611B1 (en) * 2011-09-15 2016-11-23 Nogra Pharma Limited Methods for monitoring responsiveness to anti-smad7 therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1788086A (zh) * 2003-04-02 2006-06-14 吉利亚尼国际有限公司 抗Smad7的反义寡核苷酸(ODN)及其在医药领域中的用途
WO2005014011A1 (en) * 2003-08-11 2005-02-17 Giuliani S.P.A. Use of smad 7 antisense oligonucleotides (odn) for the treatment of diseases mediated by the nuclear transcription factor nf-kb
CN101600460A (zh) * 2006-11-14 2009-12-09 香港大学 超声微泡介导的基因递送系统
CN102216458A (zh) * 2008-11-13 2011-10-12 朱利亚尼国际有限公司 反义组合物及其制备和使用方法

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk;Peter Broderick 等;《NATURE GENETICS》;20071014;第39卷(第11期);第1315-1317页 *
Carol.# 612229 -COLORECTAL CANCER, SUSCEPTIBILITY TO, 3;CRCS3.《OMIM》.2012,第1-6页. *
Increased Risk of Colon Cancer Associated with a Genetic Polymorphism of SMAD7;Martha L. Slattery 等;《Cancer Res.》;20100215;第70卷(第4期);第1479-1485页 *
Inhibitory effect of genistein on mouse colon cancer MC-26 cells involved TGF-b1/Smad pathway;Zengli Yu 等;《Biochemical and Biophysical Research Communications》;20050613;第333卷;第827-832页 *
Qiang Li 等.MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7.《Cancer Letters》.2013,第335卷第168-174页，尤其是摘要，Methods 2.11,结果部分2.6，. *
Smad2，Smad4，Smad7蛋白在结肠癌中的表达及意义;李志刚 等;《医学信息》;20101130;第23卷(第11期);第83页 *
Smad7 induces hepatic metastasis in colorectal cancer;SK Halder 等;《British Journal of Cancer》;20081231;第99卷;第957-965页 *
Smad7和TGF-β1在结直肠癌中的表达及意义;吴晶晶 等;《中国现代药物应用》;20100731;第4卷(第13期);第23-24页 *
转化生长因子 β 1 信号传导抵抗在结直肠癌的作用;郑金辉 等;《福建医科大学学报》;20071130;第41卷(第6期);第605-606页 *
转化生长因子-β 1、Smad3、Smad4和Smad7在结直肠癌发生中的作用;汪发勇 等;《胃肠病学》;20081231;第13卷(第5期);第281-284页 *

Also Published As

Publication number Publication date
KR20150131260A (ko) 2015-11-24
AU2014229985A1 (en) 2015-09-10
ES2673209T3 (es) 2018-06-20
HK1219489A1 (en) 2017-04-07
JP2016517401A (ja) 2016-06-16
CA2903597A1 (en) 2014-09-18
RU2674147C2 (ru) 2018-12-05
MX363746B (es) 2019-04-01
EP2970419B8 (en) 2019-12-11
CN105008394A (zh) 2015-10-28
EP2970419B1 (en) 2018-05-09
CA2903597C (en) 2023-04-04
ES2673209T8 (es) 2020-02-12
RU2015140572A (ru) 2017-04-24
JP2019026649A (ja) 2019-02-21
JP6502863B2 (ja) 2019-04-17
KR102232623B1 (ko) 2021-03-26
AU2014229985B2 (en) 2018-12-13
NZ711564A (en) 2020-04-24
MX2015013255A (es) 2015-12-15
RU2015140572A3 (enExample) 2018-03-21
WO2014140333A1 (en) 2014-09-18
EP2970419A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
CN105008394B (zh) 治疗结肠直肠癌的方法
US10006029B2 (en) Methods of treating colorectal cancer
Prekovic et al. Molecular underpinnings of enzalutamide resistance
JP7678032B2 (ja) がん療法において使用するためのデオキシシチジン誘導体又はデオキシウリジン誘導体
US20180113139A1 (en) Methods and compositions for diagnosing and treating inflammatory bowel disorders
JP2018523696A (ja) 肝疾患および状態を治療する方法および組成物
US10512641B2 (en) Chloroquine induction par-4 and treatment of cancer
EP3380615B1 (en) Il-34 antisense oligonucleotides and methods of using same
EP3752134B1 (en) Methods and compositions for treating vitiligo
WO2020256868A1 (en) Immune system modulators for the treatment of squamous lung premalignancy
TW202435875A (zh) 治療神經膠質瘤之方法
US20210072244A1 (en) Methods and compositions for treating melanoma resistant
TW201932123A (zh) 包含微小rna及其衍生物作為活性成分之藥物組成物
HK1219489B (en) Methods of treating colorectal cancer
JP2007525414A (ja) スラミン、ペントサン・ポリサルフェート、テロメラーゼアンチセンス、及びテロメラーゼ阻害剤を用いるための方法及び成分
CN113748207A (zh) 脆性x智力低下蛋白干扰寡核苷酸及其使用方法
US20230414554A1 (en) Compounds for treating hepatocellular carcinoma
EA045399B1 (ru) Олигонуклеотиды, препятствующие экспрессии белка, ассоциированного с синдромом ломкой х-хромосомы, и способы их применения

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant